Nature Cancer

(The TQCC of Nature Cancer is 25. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 500 papers]. The publications cover those that have been published in the past four years, i.e., from 2019-09-01 to 2023-09-01.)
Discovering the anticancer potential of non-oncology drugs by systematic viability profiling327
The impact of the COVID-19 pandemic on cancer care321
Pan-cancer computational histopathology reveals mutations, tumor composition and prognosis271
Pan-cancer image-based detection of clinically actionable genetic alterations270
Circulating tumor DNA and liquid biopsy in oncology252
Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab197
PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer187
Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer174
Multimodal mapping of the tumor and peripheral blood immune landscape in human pancreatic cancer173
Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma169
Imaging mass cytometry and multiplatform genomics define the phenogenomic landscape of breast cancer168
Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer141
Extracellular cGAMP is a cancer-cell-produced immunotransmitter involved in radiation-induced anticancer immunity137
A practical framework and online tool for mutational signature analyses show intertissue variation and driver dependencies137
A first-in-class polymerase theta inhibitor selectively targets homologous-recombination-deficient tumors130
Overcoming therapy resistance in EGFR-mutant lung cancer126
Pathway-based classification of glioblastoma uncovers a mitochondrial subtype with therapeutic vulnerabilities125
Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer122
Cancer-associated fibroblast compositions change with breast cancer progression linking the ratio of S100A4+ and PDPN+ CAFs to clinical outcome119
Immune awakening revealed by peripheral T cell dynamics after one cycle of immunotherapy118
The metabolic landscape of RAS-driven cancers from biology to therapy116
Gradient of Developmental and Injury Response transcriptional states defines functional vulnerabilities underpinning glioblastoma heterogeneity115
L1CAM defines the regenerative origin of metastasis-initiating cells in colorectal cancer111
Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation111
Fatty acid synthesis is required for breast cancer brain metastasis107
Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression106
The current paradigm and challenges ahead for the dormancy of disseminated tumor cells105
A unifying paradigm for transcriptional heterogeneity and squamous features in pancreatic ductal adenocarcinoma103
Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells99
Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer98
Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity97
Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy92
EZH2 inhibition activates a dsRNA–STING–interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer91
A biobank of small cell lung cancer CDX models elucidates inter- and intratumoral phenotypic heterogeneity90
Cancer vaccines: the next immunotherapy frontier89
Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer89
Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort89
The immuno-oncological challenge of COVID-1988
Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas88
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study87
Multifunctional oncolytic nanoparticles deliver self-replicating IL-12 RNA to eliminate established tumors and prime systemic immunity87
A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology86
Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia82
Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia80
Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma78
Long-distance modulation of bystander tumor cells by CD8+ T-cell-secreted IFN-γ78
Pan-cancer analysis of advanced patient tumors reveals interactions between therapy and genomic landscapes78
Bystander IFN-γ activity promotes widespread and sustained cytokine signaling altering the tumor microenvironment78
Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors77
SARS-CoV-2 infection in the Italian Veneto region: adverse outcomes in patients with cancer77
Applications of organoids for cancer biology and precision medicine77
Few-shot learning creates predictive models of drug response that translate from high-throughput screens to individual patients73
A tumor-derived type III collagen-rich ECM niche regulates tumor cell dormancy73
α-Ketoglutarate attenuates Wnt signaling and drives differentiation in colorectal cancer73
Patterns of seroconversion for SARS-CoV-2 IgG in patients with malignant disease and association with anticancer therapy72
CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity72
A systematic CRISPR screen defines mutational mechanisms underpinning signatures caused by replication errors and endogenous DNA damage71
A small-molecule allosteric inhibitor of BAX protects against doxorubicin-induced cardiomyopathy70
Cancer-associated fibroblasts in the single-cell era69
PAK4 inhibition improves PD-1 blockade immunotherapy68
Single-cell analyses reveal YAP/TAZ as regulators of stemness and cell plasticity in glioblastoma67
The T cell differentiation landscape is shaped by tumour mutations in lung cancer66
Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial65
Cell type and gene expression deconvolution with BayesPrism enables Bayesian integrative analysis across bulk and single-cell RNA sequencing in oncology64
Molecular pathogenesis and systemic therapies for hepatocellular carcinoma63
eIF5B drives integrated stress response-dependent translation of PD-L1 in lung cancer63
Three-dimensional imaging mass cytometry for highly multiplexed molecular and cellular mapping of tissues and the tumor microenvironment62
Resistance to natural killer cell immunosurveillance confers a selective advantage to polyclonal metastasis60
Age-associated mitochondrial DNA mutations cause metabolic remodeling that contributes to accelerated intestinal tumorigenesis59
Artificial intelligence in histopathology: enhancing cancer research and clinical oncology59
Crowdsourcing a crisis response for COVID-19 in oncology58
Super enhancers define regulatory subtypes and cell identity in neuroblastoma58
Prospective pan-cancer germline testing using MSK-IMPACT informs clinical translation in 751 patients with pediatric solid tumors57
Translational advances in pancreatic ductal adenocarcinoma therapy56
Melanoma-derived small extracellular vesicles induce lymphangiogenesis and metastasis through an NGFR-dependent mechanism55
Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity55
Emerging strategies for treating metastasis55
Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study55
Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia54
Bone marrow NG2+/Nestin+ mesenchymal stem cells drive DTC dormancy via TGF-β253
ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1-mutant lung cancer53
The interaction of CD4+ helper T cells with dendritic cells shapes the tumor microenvironment and immune checkpoint blockade response52
Short-term starvation reduces IGF-1 levels to sensitize lung tumors to PD-1 immune checkpoint blockade52
Resident and circulating memory T cells persist for years in melanoma patients with durable responses to immunotherapy52
Targeting public neoantigens for cancer immunotherapy52
c-Rel is a myeloid checkpoint for cancer immunotherapy51
A bright future for KRAS inhibitors50
Neutrophil oxidative stress mediates obesity-associated vascular dysfunction and metastatic transmigration49
Autophagy promotes growth of tumors with high mutational burden by inhibiting a T-cell immune response46
Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets46
The global challenge of cancer46
GD2-specific CAR T cells encapsulated in an injectable hydrogel control retinoblastoma and preserve vision45
EGFR inhibition triggers an adaptive response by co-opting antiviral signaling pathways in lung cancer44
MYCN mediates cysteine addiction and sensitizes neuroblastoma to ferroptosis44
Clonal expansion of T memory stem cells determines early anti-leukemic responses and long-term CAR T cell persistence in patients44
Targeting PUS7 suppresses tRNA pseudouridylation and glioblastoma tumorigenesis44
Targeting PAK4 to reprogram the vascular microenvironment and improve CAR-T immunotherapy for glioblastoma43
Mutant Kras co-opts a proto-oncogenic enhancer network in inflammation-induced metaplastic progenitor cells to initiate pancreatic cancer42
Dual-targeting CAR-T cells with optimal co-stimulation and metabolic fitness enhance antitumor activity and prevent escape in solid tumors42
Amending microbiota by targeting intestinal inflammation with TNF blockade attenuates development of colorectal cancer41
Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer40
Multifunctional barcoding with ClonMapper enables high-resolution study of clonal dynamics during tumor evolution and treatment40
The CIP2A–TOPBP1 axis safeguards chromosome stability and is a synthetic lethal target for BRCA-mutated cancer39
Integrative genomic analyses reveal mechanisms of glucocorticoid resistance in acute lymphoblastic leukemia39
Multimodal data integration using machine learning improves risk stratification of high-grade serous ovarian cancer39
Understanding and overcoming tumor heterogeneity in metastatic breast cancer treatment39
An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer38
A MYC and RAS co-activation signature in localized prostate cancer drives bone metastasis and castration resistance38
Engineering-enhanced CAR T cells for improved cancer therapy38
Castration-mediated IL-8 promotes myeloid infiltration and prostate cancer progression38
The present and future of PI3K inhibitors for cancer therapy38
Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study37
Dysregulation and therapeutic targeting of RNA splicing in cancer37
Intratumor heterogeneity reflects clinical disease course37
Radiation exposure elicits a neutrophil-driven response in healthy lung tissue that enhances metastatic colonization37
Astrocytic laminin-211 drives disseminated breast tumor cell dormancy in brain36
Autophagy inhibition by targeting PIKfyve potentiates response to immune checkpoint blockade in prostate cancer36
Single-cell meta-analyses reveal responses of tumor-reactive CXCL13+ T cells to immune-checkpoint blockade35
Accelerating precision medicine in metastatic prostate cancer35
Keap1 mutation renders lung adenocarcinomas dependent on Slc33a135
Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancer35
CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity35
ENO1 suppresses cancer cell ferroptosis by degrading the mRNA of iron regulatory protein 134
The proliferative history shapes the DNA methylome of B-cell tumors and predicts clinical outcome33
Combined inhibition of Aurora-A and ATR kinases results in regression of MYCN-amplified neuroblastoma33
Targeting purine synthesis in ASS1-expressing tumors enhances the response to immune checkpoint inhibitors32
Rethinking cancer clinical trials for COVID-19 and beyond32
Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors31
An artificial intelligence framework integrating longitudinal electronic health records with real-world data enables continuous pan-cancer prognostication31
Metabolic adaptation of acute lymphoblastic leukemia to the central nervous system microenvironment depends on stearoyl-CoA desaturase31
Bystander T cells in cancer immunology and therapy30
Epigenetic targeted therapy of stabilized BAP1 in ASXL1 gain-of-function mutated leukemia30
The deubiquitinase USP25 supports colonic inflammation and bacterial infection and promotes colorectal cancer30
TNF-α-producing macrophages determine subtype identity and prognosis via AP1 enhancer reprogramming in pancreatic cancer30
Selective multi-kinase inhibition sensitizes mesenchymal pancreatic cancer to immune checkpoint blockade by remodeling the tumor microenvironment29
An in vivo genome-wide CRISPR screen identifies the RNA-binding protein Staufen2 as a key regulator of myeloid leukemia29
Hotspot DNMT3A mutations in clonal hematopoiesis and acute myeloid leukemia sensitize cells to azacytidine via viral mimicry response28
Compensatory CSF2-driven macrophage activation promotes adaptive resistance to CSF1R inhibition in breast-to-brain metastasis28
The serine hydroxymethyltransferase-2 (SHMT2) initiates lymphoma development through epigenetic tumor suppressor silencing27
Multi-omic profiling of peritoneal metastases in gastric cancer identifies molecular subtypes and therapeutic vulnerabilities27
Serial single-cell genomics reveals convergent subclonal evolution of resistance as patients with early-stage breast cancer progress on endocrine plus CDK4/6 therapy27
Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia27
cfDNA methylome profiling for detection and subtyping of small cell lung cancers27
An anti-PD-1–GITR-L bispecific agonist induces GITR clustering-mediated T cell activation for cancer immunotherapy27
Mutational and functional genetics mapping of chemotherapy resistance mechanisms in relapsed acute lymphoblastic leukemia27
The cGAS–STING pathway and cancer27
Illuminating the noncoding genome in cancer26
Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders26
Pharmacological inhibition of BACE1 suppresses glioblastoma growth by stimulating macrophage phagocytosis of tumor cells26
Zeb2 drives invasive and microbiota-dependent colon carcinoma25
Activation of p38α stress-activated protein kinase drives the formation of the pre-metastatic niche in the lungs25
Targeting glutamine dependence through GLS1 inhibition suppresses ARID1A-inactivated clear cell ovarian carcinoma25
Complement activation promoted by the lectin pathway mediates C3aR-dependent sarcoma progression and immunosuppression25
The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology25
Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response25
Deep learning links histology, molecular signatures and prognosis in cancer25